ILT-2 Antibody (VMP55): sc-20065

ILT-2 Antibody (VMP55) is a mouse monoclonal IgG1 kappa light chain antibody that detects ILT-2 protein of mouse, rat, and human origin by western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and flow cytometry (FCM). ILT-2 Antibody (VMP55) is available in both non-conjugated and various conjugated forms, including agarose, horseradish peroxidase (HRP), phycoerythrin (PE), fluorescein isothiocyanate (FITC), and multiple Alexa Fluor® conjugates. The immunoglobulin-like transcript 2 (ILT-2), also referred to as CD85 or MIR7, is a 650 amino acid glycoprotein characterized by a 23 amino acid signal peptide, four extracellular C2-type immunoglobulin superfamily domains, and four intracellular immunoreceptor tyrosine-based inhibitory motifs (ITIMs). ILT-2 plays a crucial role in immune regulation by binding to major histocompatibility complex (MHC) class I molecules, which inhibits the activation of natural killer (NK) and T cells, thereby preventing excessive immune responses. The presence of ILT-2 on immune cells, such as monocytes, B cells, and dendritic cells, is vital for maintaining immune homeostasis and tolerance, particularly in preventing autoimmunity and modulating responses to pathogens. Additionally, ILT-2′s interaction with B cell antigen receptor and histocompatibility leukocyte antigens (HLA)-DR can inhibit calcium mobilization in myeloid cells, further underscoring ILT-2′s importance in immune signaling pathways. Upon tyrosine phosphorylation, ILT-2 associates with tyrosine phosphatase SHP-1, which is essential for ILT-2′s inhibitory function, making ILT-2 a significant target for research in immunology and therapeutic interventions.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

ILT-2 Antibody (VMP55) References:

1. Ig-like transcript 2 (ILT2)/leukocyte Ig-like receptor 1 (LIR1) inhibits TCR signaling and actin cytoskeleton reorganization.  |  Dietrich, J., et al. 2001. J Immunol. 166: 2514-21. PMID: 11160312
2. Soluble HLA-G and HLA-G1 expressing antigen-presenting cells inhibit T-cell alloproliferation through ILT-2/ILT-4/FasL-mediated pathways.  |  Naji, A., et al. 2007. Hum Immunol. 68: 233-9. PMID: 17400057
3. Expression of immunoglobulin-like transcript (ILT)2 and ILT3 in human gastric cancer and its clinical significance.  |  Zhang, Y., et al. 2012. Mol Med Rep. 5: 910-6. PMID: 22246571
4. Differential expression of HLA-G and ILT-2 receptor in human tuberculosis: Localized versus disseminated disease.  |  Saurabh, A., et al. 2016. Hum Immunol. 77: 746-53. PMID: 26776460
5. Soluble HLA-G and HLA-G Bearing Extracellular Vesicles Affect ILT-2 Positive and ILT-2 Negative CD8 T Cells Complementary.  |  Schwich, E., et al. 2020. Front Immunol. 11: 2046. PMID: 32973812
6. Prognostic Significance of Immune Checkpoints HLA-G/ILT-2/4 and PD-L1 in Colorectal Cancer.  |  Chen, QY., et al. 2021. Front Immunol. 12: 679090. PMID: 34054869
7. Effect of HLA-G5 Immune Checkpoint Molecule on the Expression of ILT-2, CD27, and CD38 in Splenic B cells.  |  Rohn, H., et al. 2022. J Immunol Res. 2022: 4829227. PMID: 35600048
8. Peripheral HLA-G/ILT-2 immune checkpoint axis in acute and convalescent COVID-19 patients.  |  Rohn, H., et al. 2023. Hum Immunol. 84: 393-400. PMID: 36925435
9. Elevated sHLA-G plasma levels post chemotherapy combined with ILT-2 rs10416697C allele status of the sHLA-G-related receptor predict poorest disease outcome in early triple-negative breast cancer patients.  |  Hoffmann, O., et al. 2023. Front Immunol. 14: 1188030. PMID: 37283737
10. A new human gene complex encoding the killer cell inhibitory receptors and related monocyte/macrophage receptors.  |  Wagtmann, N., et al. 1997. Curr Biol. 7: 615-8. PMID: 9259559
11. A novel immunoglobulin superfamily receptor for cellular and viral MHC class I molecules.  |  Cosman, D., et al. 1997. Immunity. 7: 273-82. PMID: 9285411
12. A common inhibitory receptor for major histocompatibility complex class I molecules on human lymphoid and myelomonocytic cells.  |  Colonna, M., et al. 1997. J Exp Med. 186: 1809-18. PMID: 9382880

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-ILT-2 Antibody (VMP55) has 6 citations in a variety of scientific publications.

Primary antibodies like Anti-ILT-2 Antibody (VMP55) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

ILT-2 Antibody (VMP55) Specifications

Alternate Product Name: ILT-2

Product Clone Name: VMP55

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG₁ kappa light chain

Amino Acids:

Epitope Target: ILT-2

Epitope Species: human

Product Reactivity/Detection: ILT-2

Species Reactivity/Detection: mouse, rat, human

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP, IF, FCM

Vialing Information: Each vial contains 200 µg IgG₁ kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 6 citations in various scientific publications

Available Conjugates/Forms for ILT-2 Antibody (VMP55): AC: Agarose, AF488: Alexa Fluor^® 488, AF546: Alexa Fluor^® 546, AF594: Alexa Fluor^® 594, AF647: Alexa Fluor^® 647, AF680: Alexa Fluor^® 680, AF790: Alexa Fluor^® 790, FITC: Fluoroscein, HRP: Horseradish Peroxidase, PE: Phycoerythrin